---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-035502"
form_type: "8-K"
ticker: "DMAA"
cik: "0002028614"
company_name: "Drugs Made In America Acquisition Corp."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:43:30.072600+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# DMAA SPAC enters $100K convertible bridge as first step of $500K financing; identifies AI/cybersecurity target

## Summary
- BV Advisory Partners provides $100K convertible note (up to $500K total) for compliance and transaction expenses.
- Note converts at 35% discount to post-merger market value, matures in 6 months, no interest, no trust account claim.
- Investor introduced potential target: enterprise AI/ML, quantum analytics, cybersecurity platform (Power Analytics Global).
- Company to pursue replacement sponsor and provide investor ≥40% sponsor-level economics; no definitive agreement yet.
- Proceeds used for audit, Nasdaq, legal, proxy, extension fees.

## SEC filing metadata
- accession: 0001213900-26-035502
- form_type: 8-K
- ticker: DMAA
- cik: 0002028614
- company_name: Drugs Made In America Acquisition Corp.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/ea0283803-8k_drugs.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-035502
- JSON: https://secwatch.observer/filing/0001213900-26-035502.json
- Plain text: https://secwatch.observer/filing/0001213900-26-035502.txt

## Source-grounded claims
- claim_id: 8eed0391a2b52895c936e59837325fed7b4651bc
  claim: Drugs Made In America Acquisition Corp. incurred convertible notes of $100,000 with BV Advisory Partners, LLC at does not bear interest maturing six months from the date of issuance.
  evidence_excerpt: On March 23, 2026, Drugs Made In America Acquisition Corp. (the " Company ") issued an interim convertible note (the " Interim Note ") to BV Advisory Partners, LLC (the " Investor ") in the principal amount of $100,000 (the " Interim Loan ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm
- claim_id: 9ae2c556b1d83e6a1b48e85660ae1ed86fb8c2d3
  claim: Drugs Made In America Acquisition Corp. entered into Investment Agreement with BV Advisory Partners, LLC valued at $500,000 (effective 2026-03-23).
  evidence_excerpt: On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm
- claim_id: c153f39cf8337af428e114c6eeaaae227ace1f3a
  claim: Drugs Made In America Acquisition Corp. entered into Interim Note with BV Advisory Partners, LLC valued at $100,000 (effective 2026-03-23).
  evidence_excerpt: issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.